{"filing":{"accession_number":"0001193125-26-304812","cik":"0001111485","ticker":"RXST","company_name":"RxSight, Inc.","form":"8-K","filing_date":"2026-07-15","report_date":null,"primary_document":"d140030d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1111485/000119312526304812/d140030d8k.htm"},"events":[{"id":18160,"run_id":16314,"accession_number":"0001193125-26-304812","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Aziz Mottiwala was appointed as President and Chief Executive Officer effective July 20, 2026, replacing Ron Kurtz, M.D., who transitioned to Chief Medical Officer. Mottiwala was also appointed to the Board of Directors with detailed employment terms including $14 million in equity awards.","company_name":"RxSight, Inc.","ticker":"RXST","filing_date":"2026-07-15","form":"8-K","submitted_at":null,"items":[{"id":16886,"accession_number":"0001193125-26-304812","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Aziz Mottiwala as President and Chief Executive Officer effective July 20, 2026, replacing Ron Kurtz, M.D. While the section also covers Kurtz's transition to Chief Medical Officer (a secondary appointment) and compensatory arrangements, the principal disclosed action is Mottiwala's appointment to the CEO role, a material executive leadership change. The filing also includes Mottiwala's appointment to the Board of Directors and detailed employment terms including $14 million in equity awards, but the core event is the CEO appointment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T20:24:50.473607+00:00","company_name":"","ticker":null,"filing_date":""},{"id":16887,"accession_number":"0001193125-26-304812","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure announces the appointment of Aziz Mottiwala as President and Chief Executive Officer effective July 20, 2026, succeeding Ron Kurtz, M.D., who transitions to Chief Medical Officer. While the filing also involves Dr. Kurtz's departure from the CEO role and Board, the principal disclosed action centers on the appointment of a new CEO with extensive commercial leadership experience in eye care. This is a material executive appointment affecting the registrant's leadership structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T20:24:50.473607+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16886,"accession_number":"0001193125-26-304812","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Aziz Mottiwala as President and Chief Executive Officer effective July 20, 2026, replacing Ron Kurtz, M.D. While the section also covers Kurtz's transition to Chief Medical Officer (a secondary appointment) and compensatory arrangements, the principal disclosed action is Mottiwala's appointment to the CEO role, a material executive leadership change. The filing also includes Mottiwala's appointment to the Board of Directors and detailed employment terms including $14 million in equity awards, but the core event is the CEO appointment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T20:24:50.473607+00:00","company_name":"RxSight, Inc.","ticker":"RXST","filing_date":"2026-07-15"},{"id":16887,"accession_number":"0001193125-26-304812","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure announces the appointment of Aziz Mottiwala as President and Chief Executive Officer effective July 20, 2026, succeeding Ron Kurtz, M.D., who transitions to Chief Medical Officer. While the filing also involves Dr. Kurtz's departure from the CEO role and Board, the principal disclosed action centers on the appointment of a new CEO with extensive commercial leadership experience in eye care. This is a material executive appointment affecting the registrant's leadership structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T20:24:50.473607+00:00","company_name":"RxSight, Inc.","ticker":"RXST","filing_date":"2026-07-15"}]}